Fosphenytoin vs. continuous midazolam for pediatric febrile status epilepticus
Masahiro Nishiyama1, Hiroaki Nagase1, Kazumi Tomioka1
1Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Insights
Fosphenytoin (fPHT) and midazolam (cMDL) are comparable second-line treatments for pediatric status epilepticus (SE). Fosphenytoin may be a safer option for patients not requiring barbiturate coma therapy.
Area of Science:
- Pediatric Neurology
- Critical Care Medicine
- Pharmacology
Background:
- Fosphenytoin (fPHT) and continuous intravenous midazolam (cMDL) are common second-line treatments for pediatric status epilepticus (SE) in Japan.
- No direct comparative studies existed between fPHT and cMDL for pediatric SE.
Purpose of the Study:
- To compare the efficacy and safety of fPHT versus cMDL as second-line treatments for pediatric convulsive SE.
- To evaluate the need for barbiturate coma therapy (BCT), recovery of consciousness, and mechanical ventilation in patients treated with fPHT or cMDL.
Main Methods:
- Retrospective study of pediatric patients admitted to Kobe Children's Hospital with convulsive SE.
- Patients received either fPHT or cMDL as second-line treatment for SE lasting over 30 minutes.
- Comparison of BCT rates, consciousness recovery, mechanical ventilation, and inotropic agent use between the two treatment groups.
Main Results:
- No significant difference in the proportion of patients requiring barbiturate coma therapy (BCT) between fPHT and cMDL groups.
- After excluding BCT patients, incomplete recovery of consciousness was more frequent with cMDL at 6 and 12 hours post-onset.
- Mechanical ventilation was required more often in the cMDL group compared to the fPHT group.
Conclusions:
- Fosphenytoin (fPHT) and midazolam (cMDL) demonstrate similar efficacy in treating pediatric status epilepticus (SE).
- Continuous intravenous midazolam (cMDL) may reduce the need for barbiturate coma therapy (BCT) compared to fPHT.
- Fosphenytoin (fPHT) appears to be a relatively safe second-line option for pediatric SE, particularly in patients not requiring BCT.
Background:
Fosphenytoin (fPHT) and continuous intravenous midazolam (cMDL) had commonly been used as second-line treatments for pediatric status epilepticus (SE) in Japan. However, there is no comparative study of these two treatments.
Methods:
We included consecutive children who 1) were admitted to Kobe Children's Hospital because of convulsion with fever and 2) were treated with either fPHT or cMDL as second-line treatment for convulsive SE lasting for longer than 30 min. We compared, between the fPHT and cMDL groups, the proportion of barbiturate coma therapy (BCT), incomplete recovery of consciousness, mechanical ventilation, and inotropic agents.
Results:
The proportion of BCT was not significantly different between the two groups (48.7% [20/41] in fPHT and 35.3% [29/82] in cMDL, p = 0.17). The prevalence of incomplete recovery of consciousness, mechanical ventilation, and inotropic agents was not different between the two groups. After excluding 49 patients treated with BCT, incomplete recovery of consciousness 6 h and 12 h after onset was more frequent in the cMDL group than in the fPHT group (71.7% vs. 33.3%, p < 0.01; 56.6% vs. 14.2%, p < 0.01; respectively). Mechanical ventilation was more frequent in the cMDL group than in the fPHT group (32.0% vs. 4.7%, p = 0.01).
Conclusions:
Our results suggest that 1) the efficacy of fPHT and cMDL is similar, although cMDL may prevent the need for BCT compared with fPHT, and 2) fPHT is relatively safe as a second-line treatment for pediatric SE in patients who do not require BCT.
Related Concept Videos
Marcia's Theory of Identity Status
Continuing Care
Continuity of a Function
Continuity Equation
The mass flow rate is expressed as:
Continuity Equation
Equation of Continuity


